Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Outi Nieminen"'
Autor:
Outi Nieminen
Publikováno v:
Ennen ja Nyt: Historian Tietosanomat, Iss 1 (2008)
Externí odkaz:
https://doaj.org/article/093c2c5701a245eb9cb453b34289267b
Publikováno v:
Pathophysiology. 24:197-203
Obstructive sleep apnea (OSA) increases cardiovascular morbidity and mortality. Little is known on acute peri-apneic hemodynamic alterations due to apneas. We assessed these rapid changes and how duration of apnea might contribute to them. Eight pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a5b17088a86bbd9d2cc34416a3d4b4b
https://doi.org/10.1016/j.pathophys.2017.05.003
https://doi.org/10.1016/j.pathophys.2017.05.003
Autor:
Outi Nieminen
Publikováno v:
Lähikuva – audiovisuaalisen kulttuurin tieteellinen julkaisu. 19:6-22
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53811372fa805037bdd977518ae53e70
https://doi.org/10.23994/lk.115900
https://doi.org/10.23994/lk.115900
Publikováno v:
Drug Information Journal. 38:253-264
This study addresses regulatory issues and problems associated with product development of biotechnological medical products and devices. Data were collected from interviews with Finnish companies, including: (1) recent startup companies and more est
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0691fb084d4c09510560afee9ecf0101
https://doi.org/10.1177/009286150403800304
https://doi.org/10.1177/009286150403800304
Publikováno v:
Drug Discovery Today. 9:387-391
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3bd5228e2afcf528272e6f7ee9fd746
https://doi.org/10.1016/s1359-6446(03)02938-6
https://doi.org/10.1016/s1359-6446(03)02938-6
Autor:
Outi Nieminen, Katrina Nordström
Publikováno v:
BioDrugs. 18:399-406
‘Biogenerics’ regulation has brought about a heated debate within the EU as the first biopharmaceuticals are going off patent. This study aims to examine the opportunities and challenges offered by biogenerics by surveying the viewpoints of exper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cab8486c53efd3decb3657ac63f19493
https://doi.org/10.2165/00063030-200418060-00005
https://doi.org/10.2165/00063030-200418060-00005
Autor:
Pekka Kurki, Outi Nieminen
Publikováno v:
International Journal of Pharmaceutical Medicine. 18:149-157
The risks of biotechnology-derived products and other biologicals are different from the risks of small chemical entities and, thus, their risk management will have special features. For many biological products, the safety is mainly dependent on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3968f07b881260d67f0c444fbd6e96f6
https://doi.org/10.2165/00124363-200418030-00003
https://doi.org/10.2165/00124363-200418030-00003
Autor:
Ylermi Soini, Joonas H. Kauppila, Reidar Grénman, Satu Tommola, Alhadi Almangush, Ibrahim O. Bello, Tuula Salo, Laura K. Mäkinen, Veli-Matti Kosma, Harri Keski-Säntti, Matti Pukkila, Petri Koivunen, Jussi Laranne, Outi Nieminen, Ilmo Leivo, Jaana Hagström
Publikováno v:
Head & Neck
Background Oral (mobile) tongue squamous cell carcinoma (SCC) is characterized by a highly variable prognosis in early-stage disease (T1/T2 N0M0). The ability to classify early oral tongue SCCs into low-risk and high-risk categories would represent a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462ada48c612786203831c44de50806e
http://hdl.handle.net/10138/232587
http://hdl.handle.net/10138/232587
Autor:
Stig Nordling, Jarmo A. Salo, Outi Nieminen, Sakari Knuutila, Pauli Puolakkainen, Arto Kokkola, Asta Varis, H. Savolainen
Publikováno v:
Cancer Genetics and Cytogenetics. 127:53-58
We screened 18 specimens of Barrett adenocarcinoma for genetic alterations using comparative genomic hybridization (CGH) to analyze DNA copy number changes. The most common gains were at 20q (56%) and 17q (39%). High-level amplifications were observe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c3bb9f24ca3e18df58a113d4c7ba8d2
https://doi.org/10.1016/s0165-4608(00)00423-4
https://doi.org/10.1016/s0165-4608(00)00423-4
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 60(3)
The Summary of Product Characteristics (SPC) approved by the European Medicines Agency (EMEA) and the Package Insert (PI) approved by the Food and Drug Administration (FDA) were examined for 32 biopharmaceutical products. The aim was to identify diff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1a3cdbc7c954d982085d533fde10a5f
https://pubmed.ncbi.nlm.nih.gov/15996576
https://pubmed.ncbi.nlm.nih.gov/15996576